sulfasalazine has been researched along with Carcinoma, Non-Small Cell Lung in 2 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sulfasalazine (SAS) is a repurposed antitumor drug which inhibits the proliferation and survival of cancer cells by inhibiting the xCT cellular antioxidant system." | 5.91 | Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. ( Bagherpoor, AJ; Kassie, F; Luo, X; Seelig, D; Shameem, M, 2023) |
| " Chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer were enrolled in a dose-escalation study (standard 3 + 3 design) of SASP in combination with cisplatin and pemetrexed." | 2.84 | Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. ( Fujita, A; Harada, T; Hirai, F; Imamura, CK; Inada, M; Iwama, E; Kishimoto, J; Mushiroda, T; Nagano, O; Nakanishi, Y; Nosaki, K; Ogata, H; Okamoto, I; Otsubo, K; Ozeki, T; Sakata, S; Saya, H; Seto, T; Suina, K; Takenoyama, M; Toyokawa, G; Tsuchihashi, K, 2017) |
| "Sulfasalazine (SAS) is a repurposed antitumor drug which inhibits the proliferation and survival of cancer cells by inhibiting the xCT cellular antioxidant system." | 1.91 | Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice. ( Bagherpoor, AJ; Kassie, F; Luo, X; Seelig, D; Shameem, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagherpoor, AJ | 1 |
| Shameem, M | 1 |
| Luo, X | 1 |
| Seelig, D | 1 |
| Kassie, F | 1 |
| Otsubo, K | 1 |
| Nosaki, K | 1 |
| Imamura, CK | 1 |
| Ogata, H | 1 |
| Fujita, A | 1 |
| Sakata, S | 1 |
| Hirai, F | 1 |
| Toyokawa, G | 1 |
| Iwama, E | 1 |
| Harada, T | 1 |
| Seto, T | 1 |
| Takenoyama, M | 1 |
| Ozeki, T | 1 |
| Mushiroda, T | 1 |
| Inada, M | 1 |
| Kishimoto, J | 1 |
| Tsuchihashi, K | 1 |
| Suina, K | 1 |
| Nagano, O | 1 |
| Saya, H | 1 |
| Nakanishi, Y | 1 |
| Okamoto, I | 1 |
1 trial available for sulfasalazine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small | 2017 |
1 other study available for sulfasalazine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Inhibition of lung adenocarcinoma by combinations of sulfasalazine (SAS) and disulfiram-copper (DSF-Cu) in cell line models and mice.
Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung | 2023 |